Literature DB >> 10618713

Inhibition of v-Abl transformation by p53 and p19ARF.

F Cong1, X Zou, K Hinrichs, K Calame, S P Goff.   

Abstract

Tumorigenesis is a multistep process that involves the activation of oncogenes and the inactivation of tumor suppressor genes. The transforming activity of the v-Abl oncogene of Abelson murine leukemia virus (A-MuLV) in immortal cell lines has been well studied, while the effects of v-Abl in primary fibroblasts are less clear. Here we show that v-Abl causes cell cycle arrest in primary mouse embryonic fibroblasts (MEFs) and elevated levels of both p53 and the cyclin-dependent kinase inhibitor p21Cip. p53-/- or p19ARF-/- MEFs were resistant to v-Abl-induced cell cycle arrest. Although wild-type MEFs were resistant to v-Abl transforming activity, p53-/- or p19ARF-/- MEFs were susceptible. The results indicate that loss of p19ARF and p53 function plays an important role during the transformation of primary cells by v-Abl. We suggest that although v-Abl is a potent oncogene, its full potential transforming activity cannot be realized until the ARF-, and p53-dependent growth inhibitory pathway is disabled. We also show that p53 is not the mediator of v-Abl toxicity in immortal fibroblasts and does not determine the susceptibility of immortal fibroblasts to v-Abl transformation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10618713     DOI: 10.1038/sj.onc.1203290

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

Review 1.  Nucleolar adaptation in human cancer.

Authors:  Leonard B Maggi; Jason D Weber
Journal:  Cancer Invest       Date:  2005       Impact factor: 2.176

2.  Plasmacytomagenesis in Eμ-v-abl transgenic mice is accelerated when apoptosis is restrained.

Authors:  Cassandra J Vandenberg; Paul Waring; Andreas Strasser; Suzanne Cory
Journal:  Blood       Date:  2014-07-01       Impact factor: 22.113

3.  Transforming growth factor β1 (TGF-β1) suppresses growth of B-cell lymphoma cells by p14(ARF)-dependent regulation of mutant p53.

Authors:  Gang Chen; Paritosh Ghosh; Thomas O'Farrell; Rachel Munk; Louis J Rezanka; Carl Y Sasaki; Dan L Longo
Journal:  J Biol Chem       Date:  2012-05-23       Impact factor: 5.157

4.  A novel ARF-binding protein (LZAP) alters ARF regulation of HDM2.

Authors:  Jialiang Wang; Xiaping He; Ying Luo; Wendell G Yarbrough
Journal:  Biochem J       Date:  2006-01-15       Impact factor: 3.857

5.  ARF function does not require p53 stabilization or Mdm2 relocalization.

Authors:  Chandrashekhar Korgaonkar; Lili Zhao; Modestos Modestou; Dawn E Quelle
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

6.  p19ARF determines the balance between normal cell proliferation rate and apoptosis during mammary gland development.

Authors:  Yijun Yi; Anne Shepard; Frances Kittrell; Biserka Mulac-Jericevic; Daniel Medina; Thenaa K Said
Journal:  Mol Biol Cell       Date:  2004-05       Impact factor: 4.138

Review 7.  p53 Family and Cellular Stress Responses in Cancer.

Authors:  Johanna Pflaum; Sophie Schlosser; Martina Müller
Journal:  Front Oncol       Date:  2014-10-21       Impact factor: 6.244

8.  Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer.

Authors:  Sumaira Amir; Ai-Hong Ma; Xu-Bao Shi; Lingru Xue; Hsing-Jien Kung; Ralph W Devere White
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.